1. Home
  2. RNTX vs QXL Comparison

RNTX vs QXL Comparison

Compare RNTX & QXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.78

Market Cap

65.3M

Sector

Health Care

ML Signal

HOLD

Logo Quantum X Labs Inc. Common Stock

QXL

Quantum X Labs Inc. Common Stock

N/A

Current Price

$4.70

Market Cap

75.6M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
RNTX
QXL
Founded
2001
N/A
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
65.3M
75.6M
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
RNTX
QXL
Price
$0.78
$4.70
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
427.7K
56.9K
Earning Date
05-15-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
44.16
N/A
EPS
N/A
0.10
Revenue
N/A
$26,941,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$47.10
Revenue Growth
N/A
N/A
52 Week Low
$0.69
$4.05
52 Week High
$2.18
$7.70

Technical Indicators

Market Signals
Indicator
RNTX
QXL
Relative Strength Index (RSI) 44.63 47.64
Support Level $0.69 $4.12
Resistance Level $0.88 $5.04
Average True Range (ATR) 0.06 0.35
MACD 0.01 0.07
Stochastic Oscillator 19.75 65.91

Price Performance

Historical Comparison
RNTX
QXL

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

About QXL Quantum X Labs Inc. Common Stock

Quantum X Labs Inc is an Israel-based multi-disciplinary quantum technology company focused on the research, development, and commercialization of quantum technologies and intellectual property. The company operates across a broad range of domains, including quantum computing, quantum sensing, navigation systems, atomic clocks, and quantum algorithms, with applications spanning defense, aerospace, transportation, cybersecurity, and life sciences.

Share on Social Networks: